Arturo Valle-Mendiola

Dr. Arturo Valle-Mendiola

FES Zaragoza, UNAM, Mexico City, Ciudad de México, Mexico

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2020 in Cancers
Verified
Journal Article
Open access
PDF file
AVArturo Valle-Mendiola
Arturo Valle-Mendiola
ISIsabel Soto-Cruz
Isabel Soto-Cruz
A central characteristic of many types of cancer is altered energy metabolism processes such as enhanced glucose uptake and glycolysis and decreased oxidative metabolism. The regulation of energy metabolism is an elaborate process involving regulatory proteins such as HIF (pro-metastatic protein), which reduces oxidative metabolism, and some other proteins such as tumour suppressors that promote oxidative phosphorylation. In recent years, it has been demonstrated that signal transducer and activator of transcription (STAT) proteins play a pivotal role in metabolism regulation. STAT3 and STAT5 are essential regulators of cytokine- or growth factor-induced cell survival and proliferation, as well as the crosstalk between STAT signalling and oxidative metabolism. Several reports suggest that the constitutive activation of STAT proteins promotes glycolysis through the transcriptional activation of hypoxia-inducible factors and therefore, the alteration of mitochondrial activity. It seems that STAT proteins function as an integrative centre for different growth and survival signals for energy and respiratory metabolism. This review summarises the functions of STAT3 and STAT5 in the regulation of some metabolism-related genes and the importance of oxygen in the tumour microenvironment to regulate cell metabolism, particularly in the metabolic pathways that are involved in energy production in cancer cells.

24 May 2023 in Genes
Verified
Journal Article
Open access
PDF file
AVArturo Valle-Mendiola
Arturo Valle-Mendiola
AHAdriana Gutiérrez Hoya
Adriana Gutiérrez Hoya
ISIsabel Soto-Cruz
Isabel Soto-Cruz
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway constitutes a rapid signaling module from the cell surface to the nucleus, and activates different cellular responses, such as proliferation, survival, migration, invasion, and inflammation. When the JAK/STAT pathway is altered, it contributes to cancer progression and metastasis. STAT proteins play a central role in developing cervical cancer, and inhibiting the JAK/STAT signaling may be necessary to induce tumor cell death. Several cancers show continuous activation of different STATs, including cervical cancer. The constitutive activation of STAT proteins is associated with a poor prognosis and overall survival. The human papillomavirus (HPV) oncoproteins E6 and E7 play an essential role in cervical cancer progression, and they activate the JAK/STAT pathway and other signals that induce proliferation, survival, and migration of cancer cells. Moreover, there is a crosstalk between the JAK/STAT signaling cascade with other signaling pathways, where a plethora of different proteins activate to induce gene transcription and cell responses that contribute to tumor growth. Therefore, inhibition of the JAK/STAT pathway shows promise as a new target in cancer treatment. In this review, we discuss the role of the JAK/STAT pathway components and the role of the HPV oncoproteins associated with cellular malignancy through the JAK/STAT proteins and other signaling pathways to induce tumor growth.

12 May 2016 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
AVArturo Valle-Mendiola
Arturo Valle-Mendiola
AHAdriana Gutiérrez Hoya
Adriana Gutiérrez Hoya
MLMaría del Carmen Lagunas-Cruz
María del Carmen Lagunas-Cruz
BWBenny Weiss-Steider
Benny Weiss-Steider
ISIsabel Soto-Cruz
Isabel Soto-Cruz
IL-2 receptor (IL-2R) signalling is critical for normal lymphocyte proliferation, but its role in cervical cancer is not fully understood. The receptor is composed of three chains: IL-2α, IL-2β, and IL-2γ. Intracellular signalling is initiated by ligand-induced heterodimerization of the IL-2βand IL-2γchains, resulting in the activation of multiple intracellular kinases. Recently, IL-2R was shown to be expressed on nonhaematopoietic cells, especially on several types of tumour cells. However, the function of this receptor on malignant cells has not been clearly defined. The expression of IL-2R and the production of IL-2 in cervical cancer cells have been documented as well as expression of molecules of the JAK-STAT pathway. In the current review we have highlighted the differences in the responses of molecules downstream from the IL-2R in normal lymphocytes and tumour cells that could explain the presence of tumour cells in an environment in which cytotoxic lymphocytes also exist and compete and also the effect of different concentrations of IL-2 that could activate effector cells of the immune system cells, which favour the elimination of tumour cells, or concentrations that may promote a regulatory microenvironment in which tumour cells can easily grow.

18 February 2014 in Cancer Investigation
Verified
Journal Article
Closed access
AVArturo Valle-Mendiola
Arturo Valle-Mendiola
BWBenny Weiss-Steider
Benny Weiss-Steider
LRLeticia Rocha-Zavaleta
Leticia Rocha-Zavaleta
ISIsabel Soto-Cruz
Isabel Soto-Cruz
The IL-2R signaling is critical for normal lymphocyte proliferation. However, the role of the IL-2 signaling in cervical cancer is not yet fully understood. We show that in IL-2R-expressing cervical cancer cells, JAK1 molecules are not phosphorylated. At low doses of IL-2, the constitutive phosphorylation of JAK3 and STAT5 increases in the tumor cells and decreases in lymphocytes, whereas the opposite occurs at high doses of IL-2. Using AG-490, the activation of JAK3 and the proliferation of cervical cancer cells were inhibited. We describe differences in the response of molecules downstream the IL-2R in lymphocytes and tumor cells.

6 May 2019 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
AHAdriana Gutiérrez Hoya
Adriana Gutiérrez Hoya
OZOctavio Zerecero-Carreón
Octavio Zerecero-Carreón
AVArturo Valle-Mendiola
Arturo Valle-Mendiola
MMMartha Moreno-Lafont
Martha Moreno-Lafont
RLRubén López-Santiago
Rubén López-Santiago
ISIsabel Soto-Cruz
Isabel Soto-Cruz
Cervical cancer is the second most frequent cancer in women in Mexico, and its development depends on the presence of human papillomaviruses in the uterine cervix. These oncogenic viruses transform cells where the control over cell cycle disappears, and the capacity to induce apoptosis is absent. On the other hand, some mutations confer to the transformed cells the ability to evade recognition by the immune system. The expression of markers of the immune system such as CD95, MICA/B, CD39, CD73, NKp30, NKp46, CD44, CD24, NKG2A, and CTLA-4 was analysed by flow cytometry on cervical cancer cells INBL (HPV 18, stage IVB), HeLa (HPV 18), CaSki (HPV 16), and C33A (HPV-). Our results showed the presence of atypical markers on cervical cancer cells; some of them are molecules involved in tumour cell recognition such as MICA/B and CD95. Other markers associated with immune system escape, such as CD39, CD73, and CTLA-4, were also present. Furthermore, we found that some cervical cancer cells expressed typical markers of NK cells like NKp30, NKp46, NKG2A, and KIR3DL1. It is not clear whether these molecules confer any gain to the tumour cells or if they represent a disadvantage, but we hypothesise that these molecules that are present in cervical cancer cells allow them to mimic in front of the immune system.

1 June 2004 in Cellular Signalling
Verified
Journal Article
Closed access
LRLeticia Rocha-Zavaleta
Leticia Rocha-Zavaleta
CHCarlos Huitron
Carlos Huitron
JCJulio R. Cacéres-Cortés
Julio R. Cacéres-Cortés
JAJosé A. Alvarado-Moreno
José A. Alvarado-Moreno
AVArturo Valle-Mendiola
Arturo Valle-Mendiola
RRRosalva Rangel-Corona
Rosalva Rangel-Corona